Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers
NCT ID: NCT00752141
Last Updated: 2011-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
153 participants
INTERVENTIONAL
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
oral oxybutynin
oxybutynin chloride immediate-release
capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
2
oxybutynin topical gel
oxybutynin chloride topical gel
oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
3
placebo tablets plus placebo gel
placebo
capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
oxybutynin chloride immediate-release
capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
oxybutynin chloride topical gel
oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
placebo
capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* English as a primary language
* Given written informed consent by signing and dating an informed consent form prior to study entry
Exclusion Criteria
* History of narrow-angle glaucoma or urinary or gastric retention
* Current use of drugs known to effect memory and cognition
60 Years
79 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Watson Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
National City, California, United States
Maitland, Florida, United States
Naples, Florida, United States
Ocala, Florida, United States
Atlanta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Kay GG, Staskin DR, MacDiarmid S, McIlwain M, Dahl NV. Cognitive effects of oxybutynin chloride topical gel in older healthy subjects: a 1-week, randomized, double-blind, placebo- and active-controlled study. Clin Drug Investig. 2012 Oct 1;32(10):707-14. doi: 10.1007/BF03261924.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OTG0801
Identifier Type: -
Identifier Source: org_study_id